MYELOID NEOPLASIA TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)

نویسندگان

  • Olivier Kosmider
  • Véronique Gelsi-Boyer
  • Meyling Cheok
  • Sophie Grabar
  • Véronique Della-Valle
  • Françoise Picard
  • Franck Viguié
  • Bruno Quesnel
  • Odile Beyne-Rauzy
  • Eric Solary
  • Norbert Vey
  • Mathilde Hunault-Berger
  • Pierre Fenaux
  • Véronique Mansat-De Mas
  • Eric Delabesse
  • Philippe Guardiola
  • Catherine Lacombe
  • William Vainchenker
  • Claude Preudhomme
  • François Dreyfus
  • Olivier A. Bernard
  • Daniel Birnbaum
چکیده

*Olivier Kosmider,1-5 *Véronique Gelsi-Boyer,6 Meyling Cheok,7,8 Sophie Grabar,5,9 Véronique Della-Valle,5,10 Françoise Picard,1,5 Franck Viguié,1,5 Bruno Quesnel,7,11 Odile Beyne-Rauzy,12 Eric Solary,13 Norbert Vey,14 Mathilde Hunault-Berger,15 Pierre Fenaux,16 Véronique Mansat-De Mas,17 Eric Delabesse,17 Philippe Guardiola,15 Catherine Lacombe,1-5 William Vainchenker,18 Claude Preudhomme,7,8 François Dreyfus,2-5,19 Olivier A. Bernard,1,5,10 Daniel Birnbaum,6 and Michaëla Fontenay,1-5 on behalf of the Groupe Francophone des Myélodysplasies

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

Oncogenic pathways underlying in the development of myelodysplastic syndromes (MDS) remain poorly characterized, but mutations of the ten-eleven translocation 2 (TET2) gene are frequently observed. In the present work, we evaluated the prognostic impact of TET2 mutations in MDS. Frameshift, nonsense, missense mutations, or defects in gene structure were identified in 22 (22.9%) of 96 patients (...

متن کامل

The genetic basis of myelodysplasia and its clinical relevance.

Myelodysplasia is a diagnostic feature of myelodysplastic syndromes (MDSs) but is also found in other myeloid neoplasms. Its molecular basis has been recently elucidated by means of massive parallel sequencing studies. About 90% of MDS patients carry ≥1 oncogenic mutations, and two thirds of them are found in individuals with a normal karyotype. Driver mutant genes include those of RNA splicing...

متن کامل

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders

Polycomb group (PcG) proteins are essential regulators of hematopoietic stem cells. Recent extensive mutation analyses of the myeloid malignancies have revealed that inactivating somatic mutations in PcG genes such as EZH2 and ASXL1 occur frequently in patients with myelodysplastic disorders including myelodysplastic syndromes (MDSs) and MDS/myeloproliferative neoplasm (MPN) overlap disorders (...

متن کامل

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes

Alterations of epigenetic marks are thought to play an important role in myeloid malignancies. In particular, aberrant DNA methylation is a hallmark of these diseases. DNMT3A and DNMT3B methyltransferases have predominant role in de novo methylation of DNA. Mutations in DNMT3A have been found in roughly 20% of acute myeloid leukemia (AML). The precise mechanism by which DNMT3A may affect DNA me...

متن کامل

Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis

Tet methylcytosine dioxygenase2 gene (TET2) is one of the most frequently mutated gene in myeloid neoplasm, but the prognostic role of TET2 aberrations in myelodysplastic syndromes (MDS) remains unclear. Therefore, we performed a meta-analysis. Fourteen eligible studies with 1983 patients were included in this meta-analysis. Among these, 2 studies evaluated the impact that the TET2 expression l...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2009